This information was published on 2025-09-10T07:07:24 for IP Right Acceptance Published.
| Field | Value |
| (210) | 2583252 |
| (220) |
03 Sep 2025
|
| (300) |
US, 12 Mar 2025, 99/080,151
|
| (511) (510) |
Class 42
Pharmaceutical research services, namely, nucleic acid molecule development and nucleic acid molecule delivery development and production; genetic engineering services utilizing a collection of genetic technologies for the production and delivery of immune modulators; scientific, laboratory and medical research in the field of genetic engineering technologies; scientific laboratories performing nucleic acid molecule development and nucleic acid molecule delivery development; scientific research and development, namely, development of nucleic acid molecule and nucleic acid molecule delivery for others |
| (540) | VELOCIVAX |
| (550) | Word |
| (730) |
Regeneron Pharmaceuticals, Inc.
|
| (750) |
PHILLIPS ORMONDE FITZPATRICK
|
Find out more about publications on the About page.